絞り込み

18440

広告

温暖化対策強化、100人分訴え (毎日新聞)

若者グループが25日夕、政府などに地球温暖化対策の強化を訴える活動を全国各地で行った。東京都千代田区の国会前では、「迫り来るタイムリミット」「石炭だめ」などのメ...

  1. 新型コロナ GoTo事業者、来月募集 「...
  2. 検証:異常気象、新たな日常 米で熱波/北...
  3. 新型コロナ 全国新たに576人 (毎日新...
  4. 新型コロナ 接種主体は市町村に ワクチン...

ニュース一覧

Edoxaban: Review of Pharmacology and Key Phase I to III Clinical Trials.

著者 Plitt A , Giugliano RP この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (212view , 0users)
Vitamin K antagonists (VKAs) remain the standard therapy for anticoagulation in prevention and treatment of venous thromboembolism (VTE) and for the prevention of stroke in atrial fibrillation (AF). Due to numerous limitations of VKAs, target-specific oral anticoagulants have been developed. Edoxaban is a direct activated factor X inhibitor with attractive features among which are once daily dosing, no need for routine monitoring, and minimal drug-drug interactions. In patients undergoing orthopedic surgery, edoxaban was superior to enoxaparin in preventing VTE. Furthermore, a recent large-scale phase III trial in patients with symptomatic VTE demonstrated that edoxaban was noninferior to warfarin in preventing recurrent VTE and reduced bleeding. In the largest trial of anticoagulation in patients with AF to date, edoxaban was noninferior to warfarin in the prevention of stroke or systemic embolism and reduced bleeding and cardiovascular mortality. This review provides an overview of the pharmacology, clinical trial results, and potential indications for edoxaban.
PMID: 24607764 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード